Patrick Campbell

An analysis of data obtained from urine samples in the MUSE and TULIP-1 trial sheds new light on the clinical utility of the RAIL score for identifying disease activity and treatment responders in SLE patients with and without lupus nephritis, respectively

An analysis of Medcare claims data offers clinicians an overview or the effectiveness of sarilumab and tocilizumab in second- and third-line polymyalgia rheumatica treatments relative to conventional immunomodulators, such as methotrexate or azathioprine.

An analysis of data from the National Inpatient Sample offers an overview of risk for adverse delivery outcomes associated with Takayasu arteritis among a real-world cohort of US-based patients.

An analysis of more than 250 pregnancies among women with SLE from the Hopkins Lupus Cohort provides insight into risk of adverse pregnancy outcomes based on serum 25-hydroxy vitamin D levels using real-world data.

An analysis of the National Inpatient Sample offers a deep dive into the risk of adverse outcomes associated with presence of polymyositis or dermatomyositis among patients with congestive heart failure.

Pooled data from the phase 3 TULIP program offer additional insight into the effects of anifrolumab use in people with moderate-to-severe systemic lupus erythematosus.

An analysis of more than 1 million AFib hospitalizations suggests those with large vessel vasculitis had a nearly 2-fold increase in risk of acute myocardial infarction and a more than 9-fold increase in risk of acute kidney injury.

Data from an analysis of kidney biopsies from the AURORA 2 trial presented at CCR East 2023 offer new insight into the long-term histological impact of voclosporin use on renal function in patients with lupus nephritis.

New research from a first-in-human study of a novel procedure involving electroporation of the superficial layer of the mucosa in the small intestine could help eliminate need for insulin in some people with type 2 diabetes.

An analysis of more than 1.8 million mother-offspring pairs offers new insight into a potential association between exposure to maternal depression/anxiety during pregnancy and risk of type 1 diabetes in offspring during adolescence.

An analysis of more than 4000 people from a university hospital in Japan details the impact of the COVID-19 pandemic on glycemic control and lipid profiles among people with diabetes.

Each month, our editorial staff compiles a recap of the top news in cardiology from the past month. Our April 2023 month in review features new data and documents related to heart failure management, recaps and forecasts of top regulatory decisions, and other top news!

Each month, our editorial staff compiles a recap of the top news in endocrinology from the past month. Our April 2023 month in review features top new studies, FDA approvals, and an overview of news surrounding Abbott readers.

Announced on May 1, the CRL from the FDA expressed concerns related to manufacturing control strategy, but did not express concern related to clinical data submitted as part of the NDA package for TransCon PTH.

Data from a secondary analysis of a randomized controlled trial provide an overview of the cardiovascular safety of trastuzumab biosimilar SB3 compared to the reference agent.

Leveraging data from the UK Biobank study, a new study offers insight into the risk of new-onset heart failure based on female reproductive risk factors among a cohort more than 220,000 women.

An analysis of data from more than 119,000 pregnancies suggests women with prenatal depression were at increased risk for multiple forms of cardiovascular disease within the first 2 years following delivery relative to their counterparts without prenatal depression.

A study of more than 3000 Mediterranean adults is shedding light on the impact of longer midday naps on risk of metabolic syndrome, fasting glucose, and diastolic blood pressure.

Data from the SURMOUNT-2 trial demonstrate use of tirzepatide 10 mg and 15 mg were associated with mean weight reductions of 13.4% and 15.7%, respectively, with more than 80% of tirzepatide users achieving a body weight reduction of 5% or greater.

A prespecified analysis of the DELIVER trial provides insight into the effects of dapagliflozin use on total heart failure events in patients with mildly reduced or preserved ejection fraction.

Data from the SPRINT MIND trial suggests intensive blood pressuring-lowering was associated with slower increases in white matter lesions and improved cerebral blood flow.

New data from the POISE-3 trial indicates adherence to a preoperative hypotension avoidance strategy was no more effective than a hypertension-avoidance strategy for reducing risk of postoperative adverse events.

Announced on April 25, 2023, the FDA's clearance of the Omnipod GO marks the first-of-its-kind for a basal-only insulin pod and is indicated for use as an insulin delivery device for people with type 2 diabetes aged 18 or older.

An analysis of data from 3 European countries provides insight into the apparent increase in risk of atrial fibrillation associated with preterm births as well as LGA or SGA births.

Data from the BRAVES trial indicates 70% of patients undergoing metabolic or bariatric surgery with histologically confirmed NASH achieved resolution at 52 weeks.

On April 19, 2023, an expert clinical decision pathway and scientific statement were published simultaneously in JACC. Both of these documents were aimed at providing an overview of heart failure with preserved ejection fraction, including diagnosis and management, based on contemporary evidence.

On April 21, 2023, Medtronic announced the long-awaited US approval of their MiniMed 780G System with Smart Guard Technology and the Guardian 4 Sensor, which has been available in Europe for nearly 3 years.

An analysis of hospitals in the Get With The Guidelines-HF program provides an overview of quality of care for patients treated at hospitals with a high proportion of Black patients relative to other hospitals within the program.

Most associate bariatric surgery with improved health outcomes, but a new study suggests clinicians and patients should be aware of potential changes in bone density brought on as a result of undergoing bariatric surgery.

A meta-analysis of trials examining use of the t:slim X2 insulin pump with Control-IQ technology, results of the study indicate use of the hybrid closed loop technology was associated with improvements in glycemic control, regardless of patient age, race, or previous CGM use.